MARKET NEWS

Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial
OncoTEX & Sterling Pharma Solutions Sign Clinical Manufacturing Agreement 
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin
Biosight Completes Enrollment in Phase 2b Study for First-Line Acute Myeloid Leukemia Therapy
Altimmune Announces New Preclinical Data for AdCOVID Demonstrating Sterilizing Immunity After a Single Intranasal Dose
Proveris Laboratories Announces Expanded Services for Spray & Aerosol Characterization of Unit-Dose Nasal Drugs

  FEATURED EDITORIAL

  COMPANY PROFILE

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through Emergent’s specialty products and contract development and manufacturing services, Emergent is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent aims to build healthier and safer communities. Emergent aspires to deliver peace of mind to its patients and customers so they can focus on what’s most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030. Click here for more.

Click to view MilliporeSigma’s latest video

  EXCLUSIVE ONLINE CONTENT

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial

AzurRx BioPharma, Inc. recently announced positive interim data from the first 18 out of 20 patients in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT),….

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab

Checkpoint Therapeutics, Inc. recently announced the completion of enrollment for the metastatic cutaneous squamous cell carcinoma (cSCC) cohort in its registration-enabling clinical trial of….

New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential

New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential

The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2….

Centogene Extends Global Parkinson’s Disease Study

Centogene Extends Global Parkinson’s Disease Study

Centogene N.V. recently announced it has extended the Rostock International Parkinson’s Disease (ROPAD) Study…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 26 – Lyophilization Manufacturing
June 2 – Capsules